<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04136756</url>
  </required_header>
  <id_info>
    <org_study_id>18-255-02</org_study_id>
    <nct_id>NCT04136756</nct_id>
  </id_info>
  <brief_title>NKTR-255 in Relapsed/Refractory Multiple Myeloma &amp; Non-Hodgkin Lymphoma</brief_title>
  <official_title>A Phase 1, Open-label, Multi-center, Dose Escalation and Dose Expansion Study of NKTR-255 in Relapsed or Refractory Hematological Malignancies</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Nektar Therapeutics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Nektar Therapeutics</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Patients will receive intravenous (IV) NKTR-255 in 21 or 28 day treatment cycles. During the&#xD;
      Part 1 dose escalation portion of the trial, patients will either receive NKTR-255 as&#xD;
      monotherapy, NKTR-255 administered as a doublet with daratumumab subcutaneous (DARZALEX&#xD;
      FASPRO TM), or NKTR-255 administered as a doublet with rituximab. After determination of the&#xD;
      recommended Phase 2 dose (RP2D) of NKTR-255, NKTR-255 will be evaluated in Part 2. During the&#xD;
      Part 2 dose expansion portion of the trial, patients will either receive NKTR-255 as&#xD;
      monotherapy, NKTR-255 administered as a doublet with daratumumab subcutaneous (DARZALEX&#xD;
      FASPRO TM), or NKTR-255 administered as a doublet with rituximab.&#xD;
&#xD;
      This is a Phase 1 study to evaluate safety and tolerability of NKTR-255 alone and in&#xD;
      combination with daratumumab or rituximab.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      NKTR-255 is a cytokine that is designed to regulate T and natural killer cell activation,&#xD;
      proliferation and promote their anti-tumor effects.&#xD;
&#xD;
      This is a Phase 1, open-label, multi-center, dose escalation, dose expansion, safety&#xD;
      follow-up, and survival follow-up of NKTR-255 as a single agent and NKTR-255 in combination&#xD;
      with DARZALEX FASPRO TM or rituximab. Study treatment is defined as any investigational&#xD;
      treatment(s) or marketed product(s), intended to be administered to a study patient according&#xD;
      to the study enrollment.&#xD;
&#xD;
      Part 1 will enroll relapsed/refractory multiple myeloma (MM) and Non-Hodgkin's Lymphoma (NHL)&#xD;
      patients. In Part 2, Cohort A will enroll NHL patients who have progressed on a chimeric&#xD;
      antigen receptor T-cell (CAR-T) product, Cohort B will enroll MM patients who previously&#xD;
      received daratumumab and other anti-CD38 therapies to receive NKTR-255 alone and/or in&#xD;
      combination with daratumumab, and Cohort C will enroll indolent Non-Hodgkin's Lymphoma (iNHL)&#xD;
      patients who previously received rituximab and other therapies to receive NKTR-255 alone&#xD;
      and/or in combination with rituximab.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 7, 2019</start_date>
  <completion_date type="Anticipated">January 2023</completion_date>
  <primary_completion_date type="Anticipated">June 2022</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of Treatment-Emergent Adverse Events and Serious Adverse Events of NKTR-255 as a single agent</measure>
    <time_frame>Through study completion, an expected average of 6 months</time_frame>
    <description>Safety and tolerability of NKTR-255 as evaluated by incidence of Dose Limiting Toxicities (DLTs), drug-related Adverse Events (AEs), Serious Adverse Events (SAEs), AEs leading to discontinuation, deaths, clinical laboratory abnormalities per CTCAE v5.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of Treatment-Emergent Adverse Events and Serious Adverse Events of NKTR-255 with daratumumab SC</measure>
    <time_frame>Through study completion, an expected average of 1 year</time_frame>
    <description>Safety and tolerability of NKTR-255 in combination with daratumumab as evaluated by incidence of drug-related AEs, SAEs, AEs leading to discontinuation, deaths, clinical laboratory abnormalities per CTCAE v5</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of Treatment-Emergent Adverse Events and Serious Adverse Events of NKTR-255 with rituximab</measure>
    <time_frame>Through study completion, an expected average of 1 year</time_frame>
    <description>Safety and tolerability of NKTR-255 in combination with rituximab as evaluated by incidence of drug-related AEs, SAEs, AEs leading to discontinuation, deaths, clinical laboratory abnormalities per CTCAE v5</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Evaluate the maximum tolerated dose (MTD) and recommended Phase 2 dose (RP2D) of NKTR-255 as a single agent</measure>
    <time_frame>Through study completion, an expected average of 6 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Evaluate the maximum tolerated dose (MTD) and recommended Phase 2 dose (RP2D) of NKTR-255 in combination with daratumumab SC</measure>
    <time_frame>Through study completion, an expected average of 1 year</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Evaluate the maximum tolerated dose (MTD) and recommended Phase 2 dose (RP2D) of NKTR-255 in combination with rituximab</measure>
    <time_frame>Through study completion, an expected average of 1 year</time_frame>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">118</enrollment>
  <condition>Multiple Myeloma</condition>
  <condition>Non-Hodgkin Lymphoma</condition>
  <condition>Indolent Non-Hodgkin Lymphoma</condition>
  <arm_group>
    <arm_group_label>Dose Escalation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Evaluation of NKTR-255 as:&#xD;
Monotherapy&#xD;
In combination with daratumumab&#xD;
In combination with rituximab&#xD;
This phase will help to determine the RP2D of NKTR-255</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose Expansion Cohort A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Evaluation of RP2D of NKTR-255 as monotherapy in patients with NHL relapsed after CAR-T</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose Expansion Cohort B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Evaluation of RP2D of NKTR-255 as monotherapy and in combination with SC daratumumab in patients with R/R MM</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose Expansion Cohort C</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Evaluation of RP2D of NKTR-255 as monotherapy and in combination with rituximab in patients with R/R iNHL</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>NKTR-255</intervention_name>
    <description>NKTR-255 administered by IV infusion every 21 or 28 days to establish safety and tolerability</description>
    <arm_group_label>Dose Escalation</arm_group_label>
    <arm_group_label>Dose Expansion Cohort A</arm_group_label>
    <arm_group_label>Dose Expansion Cohort B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>NKTR-255 Q21</intervention_name>
    <description>NKTR-255 administered by IV infusion every 21 days to establish safety and tolerability</description>
    <arm_group_label>Dose Expansion Cohort C</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rituximab</intervention_name>
    <description>Rituximab administered intravenously at specified dose on specified days</description>
    <arm_group_label>Dose Escalation</arm_group_label>
    <arm_group_label>Dose Expansion Cohort C</arm_group_label>
    <other_name>RITUXAN(R)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Daratumumab</intervention_name>
    <description>Daratumumab administered subcutaneously at specified dose on specified days</description>
    <arm_group_label>Dose Escalation</arm_group_label>
    <arm_group_label>Dose Expansion Cohort B</arm_group_label>
    <other_name>DARZALEX FASPRO(TM)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:&#xD;
&#xD;
          -  Patients must have relapsed or refractory MM or NHL with no available therapies that&#xD;
             would confer clinical benefit for their primary disease.&#xD;
&#xD;
          -  For MM patients, measurable relapsed or refractory MM as defined by the IMWG Criteria&#xD;
             (Kumar, 2016) following treatment with at least 3 lines of therapy with no other&#xD;
             available treatment that would confer benefit.&#xD;
&#xD;
          -  For NHL patients, measurable or detectable disease according to International Myeloma&#xD;
             Working Group (IMWG) and the Lugano Classification. Extranodal NHL disease that is&#xD;
             measurable by fluorodeoxyglucose-positron emission tomography (FDG-PET) imaging only&#xD;
             is allowed.&#xD;
&#xD;
          -  Estimated glomerular filtration rate (eGFR) ≥ 40 mL/min/1.73 m2.&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) performance status score ≤ 2&#xD;
&#xD;
        Patient has the following laboratory test results during Screening:&#xD;
&#xD;
          1. Absolute neutrophil count (ANC) or absolute granulocyte count (AGC) ≥ 1000/µL&#xD;
&#xD;
          2. Platelets ≥ 30,000/µL&#xD;
&#xD;
          3. Hemoglobin ≥ 8g/dL&#xD;
&#xD;
          4. Absolute lymphocytes ≥ 500/µL&#xD;
&#xD;
          5. Leukocytes ≥ 3000/µL&#xD;
&#xD;
        Patients are eligible who also meet all the following criteria in these cohorts of Part 2:&#xD;
&#xD;
        NKTR-255 Monotherapy NHL Group Only:&#xD;
&#xD;
          -  Patients with NHL who received a commercially approved CD19 CAR-T product and had PD.&#xD;
             The first dose of NKTR-255 will be administered within 30 days of the PD.&#xD;
&#xD;
        NKTR-255 with Daratumumab MM Group Only :&#xD;
&#xD;
          -  Patients with MM must have had previous exposure to proteasome inhibitor,&#xD;
             immunomodulatory agent (IMiD), and anti-CD38 therapy.&#xD;
&#xD;
          -  Patients who previously received daratumumab or other anti-CD38 therapies must have at&#xD;
             least 3 months washout.&#xD;
&#xD;
        NKTR-255 with Rituximab Group iNHL Group Only:&#xD;
&#xD;
          -  Patients with relapsed or refractory iNHL who previously progressed during or&#xD;
             following 1 or more prior systemic rituximab-containing (or another treatment with an&#xD;
             anti-CD20 antibody-containing) regimens for lymphoma.&#xD;
&#xD;
        Key Exclusion Criteria:&#xD;
&#xD;
          -  Patients who have an active, known, or suspected autoimmune disease.&#xD;
&#xD;
          -  Any treatment-related neurotoxicity or cytokine release syndrome (CRS) prior to&#xD;
             enrollment into the study should return to baseline before NKTR-255 treatment.&#xD;
&#xD;
          -  Active central nervous system (CNS) involvement with NHL.&#xD;
&#xD;
          -  Patients who have been previously treated with prior interleukin-2 or interleukin-15.&#xD;
&#xD;
          -  Patients who received daratumumab or other anti-CD38 therapies previously must have 3&#xD;
             months washout.&#xD;
&#xD;
        NOTE: Other protocol defined Inclusion/Exclusion criteria may apply&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Study Director</last_name>
    <role>Study Director</role>
    <affiliation>Nektar Therapeutics</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Nektar Recruitment</last_name>
    <phone>855-482-8676</phone>
    <email>StudyInquiry@nektar.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Medical Affairs</last_name>
    <phone>855-482-8676</phone>
    <email>medicalaffairs@nektar.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Western Regional Medical Center - CTCA</name>
      <address>
        <city>Goodyear</city>
        <state>Arizona</state>
        <zip>85338</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>City of Hope</name>
      <address>
        <city>Duarte</city>
        <state>California</state>
        <zip>91010</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of California, San Francisco</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94143</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>H. Lee Moffitt Cancer Center and Research Institute</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33612</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Winship Cancer Institute, Emory University</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Rush University Medical Center</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60612</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>University of Michigan</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of Minnesota</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55455</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>New York Medical College</name>
      <address>
        <city>Valhalla</city>
        <state>New York</state>
        <zip>10595</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Duke University Health System</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27705</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Virginia Cancer Specialists</name>
      <address>
        <city>Fairfax</city>
        <state>Virginia</state>
        <zip>22031</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of Washington</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>October 9, 2019</study_first_submitted>
  <study_first_submitted_qc>October 21, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">October 23, 2019</study_first_posted>
  <last_update_submitted>October 19, 2021</last_update_submitted>
  <last_update_submitted_qc>October 19, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 27, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>relapsed</keyword>
  <keyword>refractory</keyword>
  <keyword>NKTR-255</keyword>
  <keyword>CAR-T</keyword>
  <keyword>daratumumab subcutaneous (sc)</keyword>
  <keyword>interleukin-15 (IL-15)</keyword>
  <keyword>MM</keyword>
  <keyword>NHL</keyword>
  <keyword>indolent</keyword>
  <keyword>rituximab</keyword>
  <keyword>Truxima®</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Neoplasms, Plasma Cell</mesh_term>
    <mesh_term>Lymphoma, Non-Hodgkin</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rituximab</mesh_term>
    <mesh_term>Daratumumab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

